Full text
Earnings transcript
Read the complete earnings call transcript.
VRTX
Vertex Pharmaceuticals Incorporated
$558.88
18.88
(3.5%)
| Exchange: | NASDAQ |
| Market Cap: | 141.654B |
| Shares Outstanding: | 13.03M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | BiotechnologyView industry performance | |||||
| CEO: | Reshma Kewalramani | |||||
| Full Time Employees: | 6400 | |||||
| Address: |
| |||||
| Website: | https://www.vrtx.com |
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Click to read more…
Revenue Segmentation
Revenue by type
Revenue by region
VRTX full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of Vertex Pharmaceuticals, ticker VRTX, a powerhouse in the biotech space. If you’re looking to invest in a company that’s been making waves with its innovative therapies, stick around because we’re breaking down everything from financials to future potential. Let’s get started! So, why are we talking about Vertex Pharmaceuticals? Well, this isn’t just any biotech company—it’s a leader in developing treatments for serious diseases,…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 9,869,200 | 11,020,100 | 12,074,600 |
| Gross Profit | 8,607,000 | 9,489,600 | 10,267,500 |
| EBITDA | 4,605,200 | 486,300 | 4,866,300 |
| Operating Income | 3,832,000 | -232,900 | 4,760,700 |
| Net Income | 3,619,600 | -535,600 | 3,953,200 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 22,730,200 | 22,533,200 | 25,643,000 |
| Total Liabilities | 5,149,800 | 6,123,600 | 6,977,200 |
| Total Stockholders Equity | 17,580,400 | 16,409,600 | 18,665,800 |
| Total Debt | 808,400 | 1,749,500 | 3,693,000 |
| Cash and Cash Equivalents | 10,369,100 | 4,569,600 | 5,084,800 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 3,537,300 | -492,600 | 3,631,400 |
| Capital Expenditure | -258,399.999 | -297,700 | -437,600 |
| Free Cash Flow | 3,278,900.001 | -790,300 | 3,193,800 |
| Net Income | 3,619,600 | -535,600 | 3,953,200 |
| Net Change in Cash | -139,700 | -5,800,100 | 515,600 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 19,735,173.993 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 21,482,206.996 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 20,536,245.693 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 13,015,803.691 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 14,481,387.740 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 13,687,821.570 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 8,354,499.272 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 9,327,796.536 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 8,800,787.674 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 2,407,395.556 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 2,620,507.408 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 2,505,114.302 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 34.110 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 36.150 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 32.380 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 12 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 4 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: Vertex Pharmaceuticals reported strong financial results in Q4 2024, with revenue and net income growth exceeding expectations, as highlighted in the earnings call transcript. Key metrics such as operating cash flow and free cash flow demonstrate solid liquidity and operational efficiency, supporting sustained growth.
- Innovative Product Pipeline: The company emphasized advancements in its clinical pipeline during the Q4 2024 earnings call, with new product launches contributing to revenue growth. This focus on innovation aligns with industry trends in biotechnology, positioning VRTX as a leader in its sector.
- Strong Profitability Metrics: High gross profit margin and net profit margin (TTM) reflect efficient cost management and profitability compared to industry averages, providing a competitive edge within the biotechnology sector.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates VRTX intrinsic value between $473.09 – $477.67 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about VRTX valuation
Is Vertex Pharmaceuticals Incorporated (VRTX) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Vertex Pharmaceuticals Incorporated (VRTX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is VRTX a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether VRTX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is VRTX’s P/E ratio?
You can see VRTX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for VRTX?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is VRTX a good long-term investment?
Whether VRTX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
VRTX
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
3.5
Trading Metrics:
| Open: | 551.15 | Previous Close: | 540 | |
| Day Low: | 549.89 | Day High: | 563.8 | |
| Year Low: | 403.16 | Year High: | 563.8 | |
| Price Avg 50: | 522.84 | Price Avg 200: | 478.67 | |
| Volume: | 2.882M | Average Volume: | 1.364M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
